ArticleOpen forum infectious diseases2020
Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Pooled it
- Colistin Resistance in Critically Ill Adults: A Systematic Review of Epidemiological, Clinical, Laboratory, and Molecular Evidence.Microorganisms · 2026Review
- Risk factors, prognostic impact, and antimicrobial susceptibility profiles of carbapenem-resistant Acinetobacter baumannii bloodstream infections: a retrospective cohort study.Scientific reports · 2026Article
- Association of polymyxin B MIC with pharmacokinetic/pharmacodynamic target attainment and clinical outcomes in carbapenem-resistant enterobacterales infections.Frontiers in pharmacology · 2026Article
- Prognostic Indicators of Carbapenem-ResistantHealth science reports · 2025Review
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Revolutionizing antibiotic therapy: Polymyxin B and FeJournal of pharmaceutical analysis · 2025Article
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
- Article
- Gallium nitrate inhibits multidrug-resistant Acinetobacter baumannii isolated from bloodstream infection by disrupting multiple iron-dependent metabolic processes.BMC microbiology · 2025Article
- Molecular epidemiology and patient outcome of carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- Eravacycline Treatment for Carbapenem-ResistantInfection and drug resistance · 2025Article
- Mortality risk factors in patients with bloodstream infections due to multidrug-resistant Gram-negative bacilli.Frontiers in medicine · 2025Article
- The Microbiological Characteristics ofOpen forum infectious diseases · 2024Article
- Limited impact of bacterial virulence on early mortality risk factors in Acinetobacter baumannii bacteremia observed in a Galleria mellonella model.Scientific reports · 2024Article
- Optimizing Treatment for Carbapenem-ResistantInfection & chemotherapy · 2024Review
- Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study.Scientific reports · 2023Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant
methodsAdult patients with monomicrobial CRAB bacteremia in a 2700-bed tertiary hospital between December 2012 and December 2018 were retrospectively enrolled. Risk factors for 30-day mortality were evaluated. All isolates collected on the first day of bacteremia were subjected to colistin susceptibility testing by broth microdilution and to genotyping by multilocus sequence typing.
resultsA total of 164 patients were enrolled, and 90 (55%) died within 30 days. The most common genotype among the isolates was ST191 (49%), and 12 isolates (7%) were resistant to colistin. Genotype, colistin minimum inhibitory concentration, and colistin resistance were not significantly associated with mortality, in contrast to several clinical factors. In multivariable analysis, ineradicable or not-eradicated focus (adjusted odds ratio [aOR], 4.92; 95% CI, 1.95-12.42;
conclusionsClinical factors such as the nature of the infection source and source control, severity of bacteremia, and appropriateness of antibiotics, rather than microbiological factors, contribute to mortality in CRAB bacteremia. A specific antibiotic combination may help improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.